Renalys Pharma, Inc., a privately owned late-stage clinical biopharmaceutical firm located in Japan, declared that it has finalized patient enrollment and achieved the target case number for its registrational phase III clinical trial of...
Neurocrine Biosciences, Inc., a prominent biopharmaceutical firm concentrating on neuroscience, revealed the commencement of a phase 3 trial to assess the efficacy, safety, and tolerability of osavampator (previously known as NBI-1065845)...
The events in Badhal demonstrate why fast and precise diagnostic methods remain vital for identifying the medical source of emergency health conditions.
Exelixis, Inc., an internationally focused oncology firm, revealed findings from a subgroup analysis of the phase 3 CABINET pivotal trial involving patients with extra-pancreatic neuroendocrine tumours (epNET) originating in the gastrointestinal...
Innate Pharma SA reported that the initial patient has been dosed in its Phase 1 trial (NCT06781983), evaluating the safety and tolerability of IPH4502, a novel Antibody-Drug Conjugate (ADC), in individuals with advanced solid tumors expressing...
Novo Nordisk, a prominent global healthcare firm, reported topline outcomes from a phase 1b/2a clinical trial involving amycretin, a unimolecular GLP-1 and amylin receptor agonist designed for weekly subcutaneous administration. The study...
Rakuten Medical, Inc., a worldwide biotechnology firm focused on developing and commercializing precision, cell-targeting Alluminox platform-based photoimmunotherapy, declared the launch of its global multi-regional phase 3 clinical trial...
Jaguar Health, Inc. (Jaguar) affiliated companies Napo Pharmaceuticals (Napo) and Napo Therapeutics announced that the first patient has received a dose in the independent investigator-led POC trial of crofelemer, Jaguar's innovative plant-derived...
ENA Respiratory, a clinical-stage pharmaceutical firm focused on creating antiviral host defense immune boosters to reduce the effects of viral respiratory infections in vulnerable groups, reports that it has successfully finalized dosing for the...
Tris Pharma, Inc. (Tris), a biopharmaceutical company in the commercial stage, revealed encouraging topline findings from its ALLEVIATE-1 crucial Phase 3 clinical trial assessing cebranopadol, an experimental treatment, for addressing moderate-to...
.jpg)
, CDSCO.jpg)